Vaccine-based combination therapy improves antitumor immune responses in melanoma
Tumor-specific neoantigens (neoAgs) are unique to cancer cells, making them viable targets for therapeutic cancer vaccines. However, little is known about the mechanisms underlying these neoAg vaccines and how they compare to immune checkpoint therapy (ICT). Researchers led by Sunita Keshari, Ph.D., and Matthew Gubin, Ph.D., characterized changes within immune populations following treatment with neoAg vaccines and ICT in models of melanoma, leading them to identify cell subsets and potential biomarkers that provide insights for improving treatment strategies....